A new long-term study published in the Journal of Psychedelic Studies has found that psilocybin-assisted therapy (PAT) produced lasting relief from depression in patients with Major Depressive Disorder (MDD), with many remaining in remission five years after treatment.
The research followed 21 participants from an earlier clinical trial, with 18 completing the five-year follow-up. Results showed that 67% of patients remained in remission, while overall depression scores remained significantly lower compared to baseline. Anxiety levels and functional impairments were also reduced, and participants reported sustained improvements in empathy, self-acceptance, and personal relationships. Importantly, no severe adverse events were observed.
While some participants resumed antidepressants or pursued additional treatments during the follow-up period, researchers noted that many described a fundamentally different relationship with their symptoms, often marked by greater resilience and acceptance. The study also found that therapeutic support during and after dosing played a key role in long-term outcomes.
This marks the first clinical trial to extend psilocybin’s potential benefits for MDD out to five years, offering rare insight into the durability of psychedelic therapy. Though the findings are limited by the small sample size and additional treatments participants pursued, the results support psilocybin as a potentially transformative option for treatment-resistant depression.
Researchers emphasized that further large-scale studies are needed to confirm these outcomes, but the durability and safety profile observed here suggest psilocybin could offer a long-term alternative to conventional antidepressants, which often require daily dosing and come with significant side effects.
